<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576016</url>
  </required_header>
  <id_info>
    <org_study_id>60028820</org_study_id>
    <nct_id>NCT01576016</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead</brief_title>
  <official_title>Accent Magnetic Resonance Imaging Pacemaker and Tendril Magnetic Resonance Imaging™ Lead Investigational Device Exemption Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MRI Study is a prospective, multi-center, clinical study designed to evaluate the safety&#xD;
      and efficacy of the Accent MRI™ System in a patient population indicated for implant of a&#xD;
      pacemaker within and outside of the MRI environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MRI Study is a prospective, multi-center, clinical study designed to evaluate the safety&#xD;
      and efficacy of the Accent MRI System in a patient population indicated for implant of a&#xD;
      pacemaker within and outside of the MRI environment. The study consisted of two phases, a&#xD;
      Lead Safety Phase which evaluated the safety of the Tendril MRI lead, and an MRI Phase which&#xD;
      evaluated the safety and efficacy of the Accent MRI pacemaker system in an MRI environment.&#xD;
&#xD;
      The safety and efficacy of the Accent MRI pacemaker and Tendril MRI lead will be evaluated as&#xD;
      described below:&#xD;
&#xD;
      Lead Safety Safety of the Tendril MRI™ lead will be evaluated in terms of freedom from right&#xD;
      atrial (RA) and right ventricle (RV) lead-related complications at implant to 2 months (acute&#xD;
      timeframe), and at the 2 through the 12 month visit (chronic timeframe).&#xD;
&#xD;
      MRI Safety The safety of the Accent MRI™ system will be evaluated in terms of freedom from&#xD;
      MRI scan related complications in the month following the MRI scan.&#xD;
&#xD;
      Lead Efficacy Efficacy of the Tendril MRI™ lead will be evaluated in terms of the change in&#xD;
      atrial and ventricular capture and sensing thresholds before and after the MRI scan.&#xD;
&#xD;
      MRI Efficacy Efficacy of the Tendril MR lead will be evaluated in terms of the change in&#xD;
      bipolar atrial and ventricular capture and sensing thresholds before and after the MRI scan.&#xD;
&#xD;
      Secondary Endpoints Safety Safety of the Accent MRI™ system will be evaluated in terms of&#xD;
      freedom from system-related complications through the 12 month visit.&#xD;
&#xD;
      Efficacy Efficacy of the Tendril MRI™ lead will be evaluated in terms of the atrial and&#xD;
      ventricular capture thresholds at the MRI Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2012</start_date>
  <completion_date type="Actual">February 2, 2018</completion_date>
  <primary_completion_date type="Actual">February 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom From Right Atrial (RA) Lead-related Complications in the Acute Period</measure>
    <time_frame>Implant through 2 months</time_frame>
    <description>Percentage of patients who do not have RA lead-related complications from implant through the 2 month study visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From Right Ventricular (RV) Lead-related Complications in the Acute Time Period</measure>
    <time_frame>Implant through 2 months</time_frame>
    <description>Percentage of patients who do not have RV lead-related complications from implant through the 2 month study visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From RA Related Complications in the Chronic Period</measure>
    <time_frame>2 months through 12 months</time_frame>
    <description>Percentage of patients who do not have RA lead-related complications from the 2 month through the 12 month study visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From Right Ventricular Lead Related Complications in the Chronic Period</measure>
    <time_frame>2 months through 12 months</time_frame>
    <description>Percentage of patients who do not have RV lead-related complications from the 2 month through the 12 month study visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From MRI Scan-related Complications</measure>
    <time_frame>MRI Scan visit through 1 month after MRI scan visit</time_frame>
    <description>Percentage of patients who do not have MRI-related complications from the MRI scan visit to the 1 month post MRI scan visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Atrial Capture Threshold From Pre to Post MRI Scan</measure>
    <time_frame>MRI Scan visit to 1 month after MRI scan visit</time_frame>
    <description>Percentage of patients with an increase in RA capture thresholds of &lt;= 0.5 V, at a pulse width of 0.5 ms .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ventricular Capture Threshold Pre to Post MRI Scan</measure>
    <time_frame>MRI Scan visit to 1 month after MRI scan visit</time_frame>
    <description>Percentage of patients with an increase in RV capture thresholds of &lt;=0.5V, at a pulse width of 0.5 ms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Atrial Sense Amplitude</measure>
    <time_frame>MRI Scan visit to 1 month after MRI scan visit</time_frame>
    <description>Percentage of patients with a reduction in RA sense amplitude &lt;=50 % and sense amplitude &gt;=1.5 mV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ventricular Sense Amplitude</measure>
    <time_frame>MRI Scan visit to 1 month after the MRI Scan visit</time_frame>
    <description>Percentage of patients with an reduction in RV sense amplitude &lt;=50% and sense amplitude &gt;=5 mV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom From System-related Complications</measure>
    <time_frame>Implant through 12 months</time_frame>
    <description>Percentage of patients who do not have system-related complications from implant through the 12 month study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Capture Threshold at the MRI Visit</measure>
    <time_frame>MRI Scan visit (approx 3 months post implant)</time_frame>
    <description>Percentage of patients with RA capture threshold ≤2.0 volts (V) at the MRI visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Capture Threshold at the MRI Visit</measure>
    <time_frame>MRI Scan visit (approx 3 months post implant)</time_frame>
    <description>Percentage of patients with RV capture threshold ≤2.0 V at the MRI visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">950</enrollment>
  <condition>Adverse Effect of MRI on an Implanted Pacemaker Lead</condition>
  <condition>Adverse Effect of MRI on an Implanted Pacemaker</condition>
  <arm_group>
    <arm_group_label>Lead Safety</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accent MRI system MRI Scan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accent MRI system (lead safety)</intervention_name>
    <description>Patients implanted with an Accent MRI system</description>
    <arm_group_label>Lead Safety</arm_group_label>
    <other_name>Accent MRI pacemaker</other_name>
    <other_name>Tendril MRI lead</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accent MRI system (with MRI scan)</intervention_name>
    <description>Patients implanted with an Accent MRI system will receive an MRI scan</description>
    <arm_group_label>Accent MRI system MRI Scan Group</arm_group_label>
    <other_name>Accent MRI pacemaker</other_name>
    <other_name>Tendril MRI lead</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible patients will meet all of the following:&#xD;
&#xD;
          1. Have an approved indication per American College of Cardiology (ACC)/American Heart&#xD;
             Association (AHA)/Heart Rhythm Society (HRS) guidelines for implantation of a&#xD;
             pacemaker&#xD;
&#xD;
          2. Will receive a new pacemaker and lead&#xD;
&#xD;
          3. Be willing to undergo an elective MRI scan without sedation&#xD;
&#xD;
          4. Be able to provide informed consent for study participation (legal guardian is NOT&#xD;
             acceptable)&#xD;
&#xD;
          5. Be willing and able to comply with the prescribed follow-up tests and schedule of&#xD;
             evaluations&#xD;
&#xD;
          6. Is not contraindicated for an MRI scan (per the pre-MRI safety screening form)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if they meet any of the following:&#xD;
&#xD;
          1. Are medically indicated for an MRI scan at the time of enrollment&#xD;
&#xD;
          2. Have an existing pacemaker or implantable cardioverter defibrillator (ICD). A new&#xD;
             pacemaker and lead is required for enrollment&#xD;
&#xD;
          3. Have an existing active/inactive implanted medical device, e.g., neurostimulator,&#xD;
             infusion pump, etc.&#xD;
&#xD;
          4. Have a non-MRI compatible device or material implanted (e.g., intracranial aneurysm&#xD;
             clip, non-MRI compatible devices or material, metals or alloys, etc.)&#xD;
&#xD;
          5. Have a lead extender or adaptor&#xD;
&#xD;
          6. Be unable to fit in MRI bore; will come into contact with the magnet façade inside the&#xD;
             MRI bore.&#xD;
&#xD;
          7. Have a prosthetic tricuspid heart valve&#xD;
&#xD;
          8. Are currently participating in a clinical investigation that includes an active&#xD;
             treatment arm&#xD;
&#xD;
          9. Are allergic to dexamethasone sodium phosphate (DSP)&#xD;
&#xD;
         10. Are pregnant or planning to become pregnant during the duration of the study&#xD;
&#xD;
         11. Have a life expectancy of less than 12 months due to any condition&#xD;
&#xD;
         12. Patients with exclusion criteria required by local law (e.g., age)&#xD;
&#xD;
         13. Are unable to comply with the follow up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Kim</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Devices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arrhythmia Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Northwest Arkansas</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Cardiology</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Schaerf, MD</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Hospital</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Cardiology, Inc / Hoag Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Cardiology Consultants</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Memorial Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Denver Cardiology Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates PC</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Specialists of the Palm Beaches</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Clinic Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brevard Cardiovascular Research Associates</name>
      <address>
        <city>Rockledge</city>
        <state>Florida</state>
        <zip>32955</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Cardiovascular Services</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens Cardiology Group, PC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Heart Specialist</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoracic Cardio Healthcare Foundation</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Creighton Health</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Carolina Cardiology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Medical Center Clinical Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Cardiovascular Associates</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMH Regional Medical Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Health Center</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute at Utica</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Medical Specialists</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald Guthrie Foundation for Education and Research</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston, LLC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cardiovascular Consultants</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martha Jefferson Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cardiovascular Associates, PC</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitsap Cardiology Consultants</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Institute at Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Group</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>14450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Andrews Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <state>B Cap R</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <state>East Finland</state>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>August 16, 2019</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2020</results_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bradycardia</keyword>
  <keyword>MRI scans</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT01576016/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Lead safety phase: enrollment began on 03-30-2012 and ended on 06-18-2013; enrollment occured at 68 sites and 920 patients were enrolled.&#xD;
MRI Phase: study was approved by FDA on 03-26-2014. 255 patients were enrolled into the MRI Phase. 181 scans were completed by the 10-30-2014 cut-off date: 151 in the US, and 30 supplemental scans in Australia. The patients enrolled in the US came from the lead safety phase, the supplemental scans in Australia did not participate in lead safety phase.</recruitment_details>
      <pre_assignment_details>The MRI phase was originally designed as a randomized study, with MRI and control groups, but due to challenges encountered with patient recruitment, it was later changed to a non-randomized study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lead Safety Phase</title>
          <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
        </group>
        <group group_id="P2">
          <title>MRI Safety Phase</title>
          <description>A subset of patients enrolled in the Lead safety phase underwent an elective MRI scan to evaluate the safety and efficacy of Accent MRI system within the MRI environment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Lead Safety</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="920"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="647"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>System Explanted without Replacement</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsuccessful implant</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device replaced with CRT-D</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient on Palliative Care</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Too far from study site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>System deactivated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient no longer followed by study PI</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MRI Safety</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="255">255 enrollments includes 30 supplemental scans performed in Australia using the same scan protocol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-MRI Compatible Device or Material</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Has not yet completed MRI scan</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>MRI scan not performed at MRI visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A subset of participants from the lead safety phase (225) were included in the &quot;MRI Phase.&quot; 30 supplemental scans were performed in Australia for a total of 255 participants in the MRI Phase. Each Phase was analyzed separately.</population>
      <group_list>
        <group group_id="B1">
          <title>Lead Safety Phase</title>
          <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
        </group>
        <group group_id="B2">
          <title>MRI Phase</title>
          <description>A subset of patients enrolled in the Lead safety phase (225 subjects from lead safety phase) underwent an elective MRI scan to evaluate the safety and efficacy of Accent MRI system within the MRI environment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="920"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="1175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Each phase was analyzed separately.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age - Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="10.8"/>
                    <measurement group_id="B3" value="73.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age - MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="70.2" spread="11.6"/>
                    <measurement group_id="B3" value="70.2" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Each phase was analyzed separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex - Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B3" value="421"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B3" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex - MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Each phase was analyzed separately</description>
          <population>Analysis for lead safety and MRI safety phases was done separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="904"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="904"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Each phase was analyzed separately</description>
          <population>Analysis for lead safety and MRI safety phases was done separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="842"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="842"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Region of enrollment lead safety phase. Each phase of the study was analyzed separately</description>
          <population>Region of enrollment for lead safety phase only. Each phase of the study was analyzed separately</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="920"/>
                    <measurement group_id="B3" value="920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Region of enrollment MRI safety phase. Each phase of the study was analyzed separately</description>
          <population>Region of enrollment for MRI safety phase only. Each phase of the study was analyzed separately</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Indication for Pacemaker Implant</title>
          <population>Each phase was analyzed separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>AV block</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacemaker Generator Change</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prevention/Termination Of Tachyarrhythmias By Paci</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sinus Node Dysfunction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="581"/>
                    <measurement group_id="B3" value="581"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Syncope</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>AV block</title>
                  <measurement_list>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacemaker Generator Change</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prevention/Termination Of Tachyarrhythmias By Paci</title>
                  <measurement_list>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sinus Node Dysfunction</title>
                  <measurement_list>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Syncope</title>
                  <measurement_list>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular History</title>
          <population>Each phase was analyzed separately</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Coronary Artery Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myocardial Infarction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unstable Angina</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Coronary Artery Disease</title>
                  <measurement_list>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myocardial Infarction</title>
                  <measurement_list>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unstable Angina</title>
                  <measurement_list>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Cardiac Interventions</title>
          <population>Each phase was analyzed separately</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lead Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Ablation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Coronary Artery Bypass Graft</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PTCA/Stents/Atherectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI Safety Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Ablation</title>
                  <measurement_list>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Coronary Artery Bypass Graft</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PTCA/Stents/Atherectomy</title>
                  <measurement_list>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-Ventricular Arrhythmia History</title>
          <description>Each phase was analyzed separately</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Paroxysmal AF - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal AF - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent AF - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent AF - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent AF - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent AF - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Flutter - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Flutter - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Tachycardia - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Tachycardia - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supra Ventricular - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supra Ventricular - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None - lead safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None - MRI safety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="920"/>
                    <count group_id="B2" value="255"/>
                    <count group_id="B3" value="1175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Right Atrial (RA) Lead-related Complications in the Acute Period</title>
        <description>Percentage of patients who do not have RA lead-related complications from implant through the 2 month study visit</description>
        <time_frame>Implant through 2 months</time_frame>
        <population>99 of the 920 enrolled subjects had no RA lead and hence did not contribute any data towards this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Lead Safety Phase</title>
            <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Right Atrial (RA) Lead-related Complications in the Acute Period</title>
          <description>Percentage of patients who do not have RA lead-related complications from implant through the 2 month study visit</description>
          <population>99 of the 920 enrolled subjects had no RA lead and hence did not contribute any data towards this endpoint.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="821"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="95.81" upper_limit="98.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Right Ventricular (RV) Lead-related Complications in the Acute Time Period</title>
        <description>Percentage of patients who do not have RV lead-related complications from implant through the 2 month study visit</description>
        <time_frame>Implant through 2 months</time_frame>
        <population>one of 920 enrolled subjects did not have an RV lead implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Lead Safety Phase</title>
            <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Right Ventricular (RV) Lead-related Complications in the Acute Time Period</title>
          <description>Percentage of patients who do not have RV lead-related complications from implant through the 2 month study visit</description>
          <population>one of 920 enrolled subjects did not have an RV lead implanted.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="919"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.45" lower_limit="96.81" upper_limit="99.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From RA Related Complications in the Chronic Period</title>
        <description>Percentage of patients who do not have RA lead-related complications from the 2 month through the 12 month study visit</description>
        <time_frame>2 months through 12 months</time_frame>
        <population>Data from 114 subjects were unavailable for this endpoint analysis due to the following reasons: no RA lead: 99; death: 8; unsuccessful implant: 2; withdrawal:5.</population>
        <group_list>
          <group group_id="O1">
            <title>Lead Safety Phase</title>
            <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From RA Related Complications in the Chronic Period</title>
          <description>Percentage of patients who do not have RA lead-related complications from the 2 month through the 12 month study visit</description>
          <population>Data from 114 subjects were unavailable for this endpoint analysis due to the following reasons: no RA lead: 99; death: 8; unsuccessful implant: 2; withdrawal:5.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.82" lower_limit="97.04" upper_limit="99.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Right Ventricular Lead Related Complications in the Chronic Period</title>
        <description>Percentage of patients who do not have RV lead-related complications from the 2 month through the 12 month study visit</description>
        <time_frame>2 months through 12 months</time_frame>
        <population>Data from 18 subjects were unavailable for this endpoint analysis due to the following reasons: no RV lead: 1; death: 9; unsuccessful implant: 2; withdrawal: 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Lead Safety Phase</title>
            <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Right Ventricular Lead Related Complications in the Chronic Period</title>
          <description>Percentage of patients who do not have RV lead-related complications from the 2 month through the 12 month study visit</description>
          <population>Data from 18 subjects were unavailable for this endpoint analysis due to the following reasons: no RV lead: 1; death: 9; unsuccessful implant: 2; withdrawal: 6.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="902"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From MRI Scan-related Complications</title>
        <description>Percentage of patients who do not have MRI-related complications from the MRI scan visit to the 1 month post MRI scan visit</description>
        <time_frame>MRI Scan visit through 1 month after MRI scan visit</time_frame>
        <population>151 of the 255 patients enrolled received an MRI scan. An additional 30 scans were performed using an identical scan protocol implemented in this study, for a total of 181 patients who underwent an MRI scan.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Safety Phase</title>
            <description>Evaluate the safety and efficacy of the St. Jude Medical Brady MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From MRI Scan-related Complications</title>
          <description>Percentage of patients who do not have MRI-related complications from the MRI scan visit to the 1 month post MRI scan visit</description>
          <population>151 of the 255 patients enrolled received an MRI scan. An additional 30 scans were performed using an identical scan protocol implemented in this study, for a total of 181 patients who underwent an MRI scan.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.37" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Atrial Capture Threshold From Pre to Post MRI Scan</title>
        <description>Percentage of patients with an increase in RA capture thresholds of &lt;= 0.5 V, at a pulse width of 0.5 ms .</description>
        <time_frame>MRI Scan visit to 1 month after MRI scan visit</time_frame>
        <population>37 of the 181 subjects that underwent a MRI scan did not have RA capture threshold data at 1-month post scan; no RA lead: 10; RA lead off: 3; atrial fibrillation (AF/AFl) during measurement: 10; 1-month visit not completed: 14.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Efficacy Phase</title>
            <description>Evaluate the efficacy of the St. Jude Medical Brady MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atrial Capture Threshold From Pre to Post MRI Scan</title>
          <description>Percentage of patients with an increase in RA capture thresholds of &lt;= 0.5 V, at a pulse width of 0.5 ms .</description>
          <population>37 of the 181 subjects that underwent a MRI scan did not have RA capture threshold data at 1-month post scan; no RA lead: 10; RA lead off: 3; atrial fibrillation (AF/AFl) during measurement: 10; 1-month visit not completed: 14.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.47" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Ventricular Capture Threshold Pre to Post MRI Scan</title>
        <description>Percentage of patients with an increase in RV capture thresholds of &lt;=0.5V, at a pulse width of 0.5 ms.</description>
        <time_frame>MRI Scan visit to 1 month after MRI scan visit</time_frame>
        <population>167 of the 181 subjects with an MRI scan had completed the 1-month post MRI visit. Data from 167 subjects was available for this analysis; 13 subjects had not completed 1 month follow-up, 1 subject had RV capture threshold missing or not done.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Efficacy Phase</title>
            <description>Evaluate the efficacy of the St. Jude Medical Brady MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventricular Capture Threshold Pre to Post MRI Scan</title>
          <description>Percentage of patients with an increase in RV capture thresholds of &lt;=0.5V, at a pulse width of 0.5 ms.</description>
          <population>167 of the 181 subjects with an MRI scan had completed the 1-month post MRI visit. Data from 167 subjects was available for this analysis; 13 subjects had not completed 1 month follow-up, 1 subject had RV capture threshold missing or not done.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.82" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Atrial Sense Amplitude</title>
        <description>Percentage of patients with a reduction in RA sense amplitude &lt;=50 % and sense amplitude &gt;=1.5 mV.</description>
        <time_frame>MRI Scan visit to 1 month after MRI scan visit</time_frame>
        <population>60 of the 181 subjects that underwent an MRI scan did not have RA sense amplitude data: no RA lead: 10; RA lead off: 3; AF/AFl/ heart rate&lt; 30 bpm/ no P-wave during measurement: 11; P-wave &lt; 1.5 mV: 23; 1-month visit not yet completed: 12; AF/AFl during 1-month measurement: 1</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Efficacy Phase</title>
            <description>Evaluate the efficacy of the St. Jude Medical Brady MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atrial Sense Amplitude</title>
          <description>Percentage of patients with a reduction in RA sense amplitude &lt;=50 % and sense amplitude &gt;=1.5 mV.</description>
          <population>60 of the 181 subjects that underwent an MRI scan did not have RA sense amplitude data: no RA lead: 10; RA lead off: 3; AF/AFl/ heart rate&lt; 30 bpm/ no P-wave during measurement: 11; P-wave &lt; 1.5 mV: 23; 1-month visit not yet completed: 12; AF/AFl during 1-month measurement: 1</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.56" lower_limit="86.35" upper_limit="96.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Ventricular Sense Amplitude</title>
        <description>Percentage of patients with an reduction in RV sense amplitude &lt;=50% and sense amplitude &gt;=5 mV.</description>
        <time_frame>MRI Scan visit to 1 month after the MRI Scan visit</time_frame>
        <population>47 of 181 subjects that underwent an MRI scan did not have RV sense amplitude: no R-wave/HR &lt; 30 beats per minute (BPM): 18; R-wave amplitude &lt; 5 mV: 18; one-month visit not completed: 11. 134 subjects were available for evaluation of endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Efficacy Phase</title>
            <description>Evaluate the efficacy of the St. Jude Medical Brady MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventricular Sense Amplitude</title>
          <description>Percentage of patients with an reduction in RV sense amplitude &lt;=50% and sense amplitude &gt;=5 mV.</description>
          <population>47 of 181 subjects that underwent an MRI scan did not have RV sense amplitude: no R-wave/HR &lt; 30 beats per minute (BPM): 18; R-wave amplitude &lt; 5 mV: 18; one-month visit not completed: 11. 134 subjects were available for evaluation of endpoint.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.76" lower_limit="93.6" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From System-related Complications</title>
        <description>Percentage of patients who do not have system-related complications from implant through the 12 month study visit</description>
        <time_frame>Implant through 12 months</time_frame>
        <population>All subjects enrolled in the lead-safety arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Lead Safety Phase</title>
            <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From System-related Complications</title>
          <description>Percentage of patients who do not have system-related complications from implant through the 12 month study visit</description>
          <population>All subjects enrolled in the lead-safety arm.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="920"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.64" lower_limit="92.76" upper_limit="96.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Capture Threshold at the MRI Visit</title>
        <description>Percentage of patients with RA capture threshold ≤2.0 volts (V) at the MRI visit</description>
        <time_frame>MRI Scan visit (approx 3 months post implant)</time_frame>
        <population>23 of the 181 subjects that underwent an MRI scan did not have RA capture threshold for the MRI scan visit: no RA lead: 10; RA lead off: 3; AF/AFl during measurement: 10.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Efficacy Phase</title>
            <description>Evaluate the efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Capture Threshold at the MRI Visit</title>
          <description>Percentage of patients with RA capture threshold ≤2.0 volts (V) at the MRI visit</description>
          <population>23 of the 181 subjects that underwent an MRI scan did not have RA capture threshold for the MRI scan visit: no RA lead: 10; RA lead off: 3; AF/AFl during measurement: 10.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="97.69" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Capture Threshold at the MRI Visit</title>
        <description>Percentage of patients with RV capture threshold ≤2.0 V at the MRI visit</description>
        <time_frame>MRI Scan visit (approx 3 months post implant)</time_frame>
        <population>All subjects that underwent a MRI scan had ventricular capture threshold data available.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Efficacy Phase</title>
            <description>Evaluate the efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Capture Threshold at the MRI Visit</title>
          <description>Percentage of patients with RV capture threshold ≤2.0 V at the MRI visit</description>
          <population>All subjects that underwent a MRI scan had ventricular capture threshold data available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="97.98" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Adverse events (AEs) are classified as complications, observations, or other reported events. An independent, Clinical Events Committee, adjudicated all adverse events reported during the MRI Study.&#xD;
Complications: AEs that require invasive intervention.&#xD;
Observations: AEs that can be managed without invasive intervention.&#xD;
Other Reported Events (ORE): Any other clinical event, which is not caused/associated with the study system component(s) and/or defined as an AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lead Safety Phase</title>
          <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker.</description>
        </group>
        <group group_id="E2">
          <title>MRI Phase</title>
          <description>Evaluate the safety and efficacy of the St. Jude Medical Accent MRI system, which includes the Tendril MRI™ lead and Accent MRI™ pacemaker, within the MRI environment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="920"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="920"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>System Related: Decompensated HF</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>System Related: Pacemaker Induced Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>RV Lead Related: Twiddler's Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>System Related: Pacemaker system relocation to right side</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>System Related: Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>System Related: Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>System Related: Cardiac Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>System Related: Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Pneumothorax</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Bleeding/Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Pocket Site/Incision Pain Lasting Greater Than 72 Hours Post Implant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Insufficient Slack in Lead</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Hemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Wound Dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>RA Lead Related: Lead Dislodgement or Migration</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RA Lead Related: Elevated Pacing Thresholds</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RA Lead Related: Cardiac Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RA Lead Related: Lead Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RA Lead Related: Undersensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RV Lead Related: Lead Dislodgement or Migration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RV Lead Related: Elevated Pacing Thresholds</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>VR Lead Related: Lead Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RV Lead Related: Loss of Capture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>RV Lead Related: Extracardiac Stimulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pacemaker Related: Device Connectivity Issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pacemaker Related: Early Battery Depletion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Device Migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Procedure Related: Stenosis of The Left Subclavian Vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Thrombo-Embolic Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="920"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ORE: Atrial Arrhythmia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="46" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ORE: Decompensated HF</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ORE: Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ORE: Chest Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ORE: Angina</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ORE: Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pacemaker Related: Pacemaker Mediated Tachycardia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="920"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedure Related: Bleeding/Hematoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Procedure Related: Pneumothorax</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>RA Lead Related: Oversensing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Procedure Related: Thrombo-Embolic Event</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>ORE: Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="920"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grant Kim, Program Director - Traditional Cardiac Rhythm Management</name_or_title>
      <organization>Abbott</organization>
      <phone>818-493-3147</phone>
      <email>grant.kim1@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

